Pliant Therapeutics Inc at Cowen Health Care Conference Transcript
I'm covering analyst, Ritu Baral. And with us from Pliant, we have President and CEO, Bernard Coulie, as well as Chief Medical Officer, Ãric Lefebvre.
Bernard, Eric, thank you so much for joining us today, and congratulations on the Bexo Phase 2 IPF data that you've been rolling out over the past six-plus months. We're going to spend most of our time discussing that today, but it's rare to be able to discuss a Phase 2 dataset and focus -- and not focus on the degree of clinical meaningful benefit and whether it is or not versus just how would it can mean for patients. So we're going to start there.
Questions & Answers
Maybe a basic mechanistic question that we never got around to on the conference calls where we seem to run out of time, given the anti-fibrotic effect that you've seen spanning in vitro studies all the way into Phase 2 now, how do you see the potential effect driven by alpha v beta 6 versus alpha v beta 1? And is there any sort of interplay? Is there any sort of
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |